{"filing":{"accession_number":"0001193125-26-380165","cik":"0001515673","ticker":"RARE","company_name":"Ultragenyx Pharmaceutical Inc.","form":"8-K","filing_date":"2026-09-02","report_date":"2026-09-02","primary_document":"rare-20260902.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526380165/rare-20260902.htm"},"events":[{"id":31278,"run_id":28693,"accession_number":"0001193125-26-380165","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Ultragenyx disclosed failure of the Phase 3 Aspire study for apazunersen (GTX-102) to meet its primary and key secondary endpoints in Angelman syndrome treatment. The company announced it will evaluate the program's disposition and implement significant expense reductions. This is a material operational/clinical event affecting the company's pipeline and future operations, but does not fit the specific categories of earnings release, material impairment, or workforce reduction—it is a clinical development setback with strategic implications.","company_name":"Ultragenyx Pharmaceutical Inc.","ticker":"RARE","filing_date":"2026-09-02","form":"8-K","submitted_at":null,"items":[{"id":34110,"accession_number":"0001193125-26-380165","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Ultragenyx disclosed failure of the Phase 3 Aspire study for apazunersen (GTX-102) to meet its primary and key secondary endpoints in Angelman syndrome treatment. The company announced it will evaluate the program's disposition and implement significant expense reductions. This is a material operational/clinical event affecting the company's pipeline and future operations, but does not fit the specific categories of earnings release, material impairment, or workforce reduction—it is a clinical development setback with strategic implications.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:05:09.894202+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34110,"accession_number":"0001193125-26-380165","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Ultragenyx disclosed failure of the Phase 3 Aspire study for apazunersen (GTX-102) to meet its primary and key secondary endpoints in Angelman syndrome treatment. The company announced it will evaluate the program's disposition and implement significant expense reductions. This is a material operational/clinical event affecting the company's pipeline and future operations, but does not fit the specific categories of earnings release, material impairment, or workforce reduction—it is a clinical development setback with strategic implications.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:05:09.894202+00:00","company_name":"Ultragenyx Pharmaceutical Inc.","ticker":"RARE","filing_date":"2026-09-02"}]}